178 related articles for article (PubMed ID: 31807302)
1. Factors associated with parathyroid hormone control in haemodialysis patients with secondary hyperparathyroidism treated with cinacalcet in real-world clinical practice: Mimosa study.
Rottembourg J; Ureña-Torres P; Toledano D; Gueutin V; Hamani A; Coldefy O; Hebibi H; Guincestre T; Emery C
Clin Kidney J; 2019 Dec; 12(6):871-879. PubMed ID: 31807302
[TBL] [Abstract][Full Text] [Related]
2. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
Torres PU
J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
[TBL] [Abstract][Full Text] [Related]
3. Severe secondary hyperparathyroidism in patients on haemodialysis is associated with a high initial serum parathyroid hormone and beta-CrossLaps level: Results from an incident cohort.
Jean G; Lafage-Proust MH; Souberbielle JC; Lechevallier S; Deleaval P; Lorriaux C; Hurot JM; Mayor B; Mehdi M; Chazot C
PLoS One; 2018; 13(6):e0199140. PubMed ID: 29912988
[TBL] [Abstract][Full Text] [Related]
4. Trajectories of CKD-MBD biochemical parameters over a 2-year period following diagnosis of secondary hyperparathyroidism: a pharmacoepidemiological study.
Filipozzi P; Ayav C; Ngueyon Sime W; Laurain E; Kessler M; Brunaud L; Frimat L
BMJ Open; 2017 Mar; 7(3):e011482. PubMed ID: 28348181
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Secondary Hyperparathyroidism and Posttransplant Tertiary Hyperparathyroidism.
Egan CE; Qazi M; Lee J; Lee-Saxton YJ; Greenberg JA; Beninato T; Zarnegar R; Fahey TJ; Finnerty BM
J Surg Res; 2023 Nov; 291():330-335. PubMed ID: 37506432
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficiency of treatment with cinacalcet of haemodialysed patients with chronic kidney disease and secondary hyperparathyroidism.
Kuczera P; Adamczak M; Więcek A
Endokrynol Pol; 2013; 64(3):176-81. PubMed ID: 23873419
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of paricalcitol versus cinacalcet with low-dose vitamin D for management of secondary hyperparathyroidism in haemodialysis patients in the USA.
Sharma A; Marshall TS; Khan SS; Johns B
Clin Drug Investig; 2014 Feb; 34(2):107-15. PubMed ID: 24214232
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of secondary hyperparathyroidism resistant to conventional therapy and tertiary hyperparathyroidism with Cinacalcet: an efficiency strategy].
Jean G; Vanel T; Terrat JC; Hurot JM; Lorriaux C; Mayor B; Deleaval P; Vovan C; Chazot C
Nephrol Ther; 2010 Apr; 6(2):105-10. PubMed ID: 20185380
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of cinacalcet with low-dose vitamin D in incident haemodialysis subjects with secondary hyperparathyroidism.
Ureña-Torres P; Bridges I; Christiano C; Cournoyer SH; Cooper K; Farouk M; Kopyt NP; Rodriguez M; Zehnder D; Covic A
Nephrol Dial Transplant; 2013 May; 28(5):1241-54. PubMed ID: 23328710
[TBL] [Abstract][Full Text] [Related]
10. Two Years of Cinacalcet Hydrochloride Treatment Decreased Parathyroid Gland Volume and Serum Parathyroid Hormone Level in Hemodialysis Patients With Advanced Secondary Hyperparathyroidism.
Yamada S; Tokumoto M; Taniguchi M; Toyonaga J; Suehiro T; Eriguchi R; Fujimi S; Ooboshi H; Kitazono T; Tsuruya K
Ther Apher Dial; 2015 Aug; 19(4):367-77. PubMed ID: 25851690
[TBL] [Abstract][Full Text] [Related]
11. Targets for parathyroid hormone in secondary hyperparathyroidism: is a "one-size-fits-all" approach appropriate? A prospective incident cohort study.
Laurain E; Ayav C; Erpelding ML; Kessler M; Briançon S; Brunaud L; Frimat L
BMC Nephrol; 2014 Aug; 15():132. PubMed ID: 25123022
[TBL] [Abstract][Full Text] [Related]
12. Economic evaluation of cinacalcet in the treatment of secondary hyperparathyroidism in Italy.
Eandi M; Pradelli L; Iannazzo S; Chiroli S; Pontoriero G
Pharmacoeconomics; 2010; 28(11):1041-54. PubMed ID: 20936886
[TBL] [Abstract][Full Text] [Related]
13. Direct in vitro evidence of the suppressive effect of cinacalcet HCl on parathyroid hormone secretion in human parathyroid cells with pathologically reduced calcium-sensing receptor levels.
Kawata T; Imanishi Y; Kobayashi K; Onoda N; Okuno S; Takemoto Y; Komo T; Tahara H; Wada M; Nagano N; Ishimura E; Miki T; Ishikawa T; Inaba M; Nishizawa Y
J Bone Miner Metab; 2006; 24(4):300-6. PubMed ID: 16816924
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of cinacalcet withdrawal in Australian dialysis patients.
Ruderman I; Holt SG; Kirkland GS; Maslen S; Hawley CM; Oliver V; Krishnasamy R; Gray NA; Talaulikar GS; Nelson CL; Rajaram Y; Gock H; Au E; Elder GJ; Mainra R; Toussaint ND
Intern Med J; 2019 Jan; 49(1):48-54. PubMed ID: 29992701
[TBL] [Abstract][Full Text] [Related]
15. Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study.
Ketteler M; Martin KJ; Cozzolino M; Goldsmith D; Sharma A; Khan S; Dumas E; Amdahl M; Marx S; Audhya P
Nephrol Dial Transplant; 2012 May; 27(5):1942-9. PubMed ID: 21931122
[TBL] [Abstract][Full Text] [Related]
16. Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism.
Koizumi M; Komaba H; Nakanishi S; Fujimori A; Fukagawa M
Nephrol Dial Transplant; 2012 Feb; 27(2):784-90. PubMed ID: 21730210
[TBL] [Abstract][Full Text] [Related]
17. [Cinacalcet treatment for secondary hyperparathyroidism in dialysis patients in real-world clinical practice - the ECHO observational study: French experience].
Ureña P; Fouque D; Brunet P; Touam M; Réglier JC
Nephrol Ther; 2012 Dec; 8(7):527-33. PubMed ID: 23018042
[TBL] [Abstract][Full Text] [Related]
18. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study.
Lindberg JS; Culleton B; Wong G; Borah MF; Clark RV; Shapiro WB; Roger SD; Husserl FE; Klassen PS; Guo MD; Albizem MB; Coburn JW
J Am Soc Nephrol; 2005 Mar; 16(3):800-7. PubMed ID: 15689407
[TBL] [Abstract][Full Text] [Related]
19. [Cinacalcet in the management of normocalcaemic secondary hyperparathyroidism after kidney transplantation: one-year follow-up multicentre study].
Torregrosa JV; Morales E; Díaz JM; Crespo J; Bravo J; Gómez G; Gentil MA; Rodríguez-Benot A; Rodríguez-García M; López-Jiménez V; Gutiérrez-Dalmau Á; Jimeno L; Pérez-Sáez MJ; Romero R; Gómez-Alamillo C;
Nefrologia; 2014; 34(1):62-8. PubMed ID: 24463864
[TBL] [Abstract][Full Text] [Related]
20. An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism.
Malluche HH; Monier-Faugere MC; Wang G; Frazã O JM; Charytan C; Coburn JW; Coyne DW; Kaplan MR; Baker N; McCary LC; Turner SA; Goodman WG
Clin Nephrol; 2008 Apr; 69(4):269-78. PubMed ID: 18397701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
